ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Losing Stock Guy: Why He Went Wrong
By Kevin Matras

Quote:

Search for Ticker

Free Membership

Search:

ANSV: Anesiva Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

ANESIVA INC (NASD)
ANSV	0.13	0.01	(8.33%)	Vol. 1,505,129	15:59 ET

Anesiva, Inc. seeks to be a leader in the development of novel pharmaceutical products for pain management. The company's lead product candidate is Adlea, a novel small molecule formulation of capsaicin that is currently in development for the management of acute pain following orthopedic surgeries. Adlea has been shown in ACTIVE-2 and in previous clinical trials to provide well-tolerated and extended pain relief after only a single administration in multiple indications for site-specific, acute and chronic, moderate-to-severe pain.

General Information

ANESIVA INC

650 Gateway Boulevard South San Francisco, CA 94080 Phone: 650 624-9600 Fax: 650 624-7540 Web: www.anesiva.com Email: investors@anesiva.com

Industry	MED-BIOMED/GENE
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	11/23/2009

Price and Volume Information

Zacks Rank
Yesterday's Close	0.12
52 Week High	1.49
52 Week Low	0.06
Beta	2.27
20 Day Moving Average	391,050.50
Target Price Consensus	N/A

% Price Change
4 Week	-34.21
12 Week	-55.04
YTD	-64.49

% Price Change Relative to S&P 500
4 Week	-34.92
12 Week	-57.61
YTD	-70.61

Share Information
Shares Outstanding (millions)	40.47
Market Capitalization (millions)	5.06
Short Ratio	0.14
Last Split Date	12/16/2005

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	N/A
Current Year EPS Consensus Estimate	N/A
Estimated Long-Term EPS Growth Rate	-
Next EPS Report Date	11/23/2009

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	3.00
30 Days Ago	3.00
60 Days Ago	3.00
90 Days Ago	3.00

Fundamental Ratios

P/E
Current FY Estimate:	-
Trailing 12 Months:	-
PEG Ratio	-

EPS Growth
vs. Previous Year	1.72%
vs. Previous Quarter	-5.56%

Sales Growth
vs. Previous Year	-98.00%
vs. Previous Quarter:	-99.67%

Price Ratios
Price/Book	-
Price/Cash Flow	-
Price / Sales	-

ROE
09/30/09	-
06/30/09	-
03/31/09	-283.25

ROA
09/30/09	31.31
06/30/09	-118.04
03/31/09	-110.99

Current Ratio
09/30/09	0.03
06/30/09	0.08
03/31/09	0.08

Quick Ratio
09/30/09	0.03
06/30/09	0.08
03/31/09	0.08

Operating Margin
09/30/09	-
06/30/09	-
03/31/09	-

Net Margin
09/30/09	-73,001.27
06/30/09	-
03/31/09	-12,582.78

Pre-Tax Margin
09/30/09	-73,001.27
06/30/09	-
03/31/09	-12,582.78

Book Value
09/30/09	-0.51
06/30/09	-0.46
03/31/09	-0.38

Inventory Turnover
09/30/09	-
06/30/09	-1.84
03/31/09	0.00

Debt-to-Equity
09/30/09	0.00
06/30/09	0.00
03/31/09	0.00

Debt to Capital
09/30/09	-
06/30/09	-
03/31/09	-


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research